Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Immuno-Oncology Technology|June 27, 2022
1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCsL E Stopfer, A D D'Souza, F M White
Immuno-Oncology Technology|June 27, 2022
Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitorsP J Vlachostergios
Immuno-Oncology Technology|June 27, 2022
Intervention strategies for microbial therapeutics in cancer immunotherapyV Gopalakrishnan, B Weiner, C B Ford, et al.
Immuno-Oncology Technology|June 27, 2022
Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptorsJ Feucht, M Sadelain
Immuno-Oncology Technology|April 16, 2025
Solid tumour cellular therapy - principles of toxicity managementM Julve, Y N S Wong, K H J Lim, et al.
Immuno-Oncology Technology|April 16, 2025
An adjusted droplet digital PCR assay for quantification of vector copy number in CAR-T cell and TCR-T cell productsJ Ma, S Meyer, J Olweus, et al.
Immuno-Oncology Technology|January 17, 2022
T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translationAmalie Kai Bentzen, Sine Reker Hadrup
Immuno-Oncology Technology|May 1, 2023
Non-viral chimeric antigen receptor (CAR) T cells going viralH Balke-Want, V Keerthi, A Cadinanos-Garai, et al.
Immuno-Oncology Technology|November 24, 2025
Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expressionF Shoji, T Kawabata, K Kosai, et al.
Immuno-Oncology Technology|January 1, 2026
Phase II trial on nivolumab plus hypofractionated radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trialM Nomura, M Yoshimura, T Yokota, et al.
Pageof 10